Novo Nordisk rolls out Powerful Diabetes & Weight-Loss Drug Ozempic Hits Indian Market at ₹2,200/Week Available in three doses, priced from ₹8,800/month. Specialist prescription only.
Novo Nordisk has officially introduced its blockbuster diabetes injection Ozempic in India, aiming to address rising cases of type-2 diabetes and related weight issues in the country. The drug, containing semaglutide, is now available in three strengths with an entry price that puts it within reach of many patients managing chronic conditions.
The Denmark-based pharmaceutical firm priced the lowest 0.25 mg weekly dose at ₹2,200, equating to about ₹8,800 per month. Higher strengths — 0.5 mg and 1 mg — carry monthly costs of roughly ₹10,170 and ₹11,175, respectively. Ozempic comes in a pre-filled pen for once-weekly injection under medical supervision.
Why Ozempic Matters to India
India has the second-highest number of people living with type-2 diabetes globally, following China, and faces a growing obesity burden. These trends have made the market a strategic focus for global drugmakers. Analysts estimate the global diabetes and obesity treatment segment could reach $150 billion annually by 2030.
Novo Nordisk’s Managing Director in India highlighted that Ozempic is being offered competitively, positioned to provide effective therapy while meeting local affordability expectations. In India, the medication is approved for type-2 diabetes and is not permitted for cosmetic weight-loss uses. Only specialist doctors can prescribe it.
Market and Future Outlook
The launch comes as several firms prepare to enter the semaglutide space with generics. Firms like Sun Pharma, Cipla, and Dr. Reddy’s are developing alternatives that could be priced up to 50 % lower once patents expire. Novo Nordisk earlier launched a related drug, Wegovy, and has adjusted pricing ahead of increased competition.
Healthcare providers and patients alike are watching closely as this new therapy becomes accessible across India’s expanding metabolic health market.